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Malaria, a devastating infectious disease caused by Plasmodium spp., leads to roughly 655,000 deaths per
year, mostly of African children. To compound the problem, drug resistance has emerged to all classical anti-
malarials and may be emerging for artemisinin-based combination therapies. To address the need for new
antimalarials with novel mechanisms, several groups carried out phenotypic screening campaigns to identify
compounds inhibiting growth of the blood stages of Plasmodium falciparum. In this review, we describe the
characterization of these compounds, explore currently ongoing strategies to develop lead molecules, and
endorse the concept of a ‘‘malaria box’’ of publicly accessible active compounds.Introduction
Malaria is a mosquito-borne disease that kills roughly 655,000
people every year, mostly young children in Africa. Malaria
affects roughly 215 million patients annually (World Health
Organization, 2011), and approximately one third of the world’s
population is at risk for contracting the disease. The World
Health Organization has announced a new campaign for global
malaria eradication (Wells et al., 2009).
Mosquito-borne diseases are usually controlled by a combina-
tion of vector control, vaccines, and chemotherapy. In the case
of malaria, economical vector control strategies, including insec-
ticide-impregnated bed nets and localized spraying, have been
deployed with success (Okumu and Moore, 2011). Additionally,
progress is being made toward effective vaccines with the
RTSS vaccine from GlaxoSmithKline (GSK), giving some protec-
tion (Schwenk and Richie, 2011). Nonetheless, chemotherapy
remains the dominant component of malaria control. Unfortu-
nately, clinical resistance has emerged for most available drugs
(Petersen et al., 2011), and there are recent indications of the
emergence of resistance to the artemisinin components of arte-
misinin-based combination therapies, which are a cornerstone
of current antimalarial treatment strategies (Dondorp et al.,
2009;Mok et al., 2011; Saralamba et al., 2011; Veiga et al., 2011).
Therefore, new antimalarials are urgently needed. The focus of
the discovery process is on new medicines that are structurally
distinct from existing drugs, act by novel mechanisms, and avoid
being acted upon by drug transporters overexpressed or over-
active in multi-drug-resistant malaria. In the late 2000s, three
groups, one in academia (St. Jude Children’s Research Hospital)
(Guiguemde et al., 2010) and two in industry (GSK [Gamo
et al., 2010] and Novartis [Plouffe et al., 2008]), identified novel
leads using screening campaigns measuring the growth inhibi-
tory potential of compounds acting on Plasmodium falciparum
co-cultured during its asexual stages in human erythrocytes.
In this review, we discuss the driving force for conducting
these screens; the results, including similarities and differences
between the compounds identified; and the need for further116 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd Allinnovation and work in understanding the underlying cellular
and physiologic mechanisms by which the new classes of anti-
malarials work.
Biology
The rate of discovery of novel antimalarials has been slow
since the 1980s, after the pharmaceutical industry deprioritized
antimalarial drug discovery. Most work until the mid-2000s
addressed two themes: (1) incremental modification of existing
chemotypes to overcome drug resistance or improve pharmaco-
logic properties; and (2) assessment of new targets proposed
from parasitologic insight. The conditions in the field—wide-
spread drug resistance to most classes of drugs, a small number
of structural classes of drugs, and a small number of validated
targets—constituted a perfect storm, occluding the develop-
ment of novel drugs.
Drug Resistance
Many targeted antimalarials seemed to rapidly lose efficacy. For
example, atovaquone, an analog of ubiquinone that selectively
inhibits the parasitic electron transport chain, selected for drug
resistance before its introduction into the market (Canfield
et al., 1995). The use of dihydrofolate reductase (DHFR)-target-
ing drugs revealed that multiple drug resistance mutations could
accumulate, conferring high levels of resistance (Sridaran et al.,
2010). This has left the impression that, in many cases, the para-
site can rapidly select for mutations that confer drug resistance
during the blood stages and that many compounds that target
specific enzymes will fall victim to this issue. On the other
hand, resistance to drugs, such as chloroquine, that do not
target enzymes seems to happen much less rapidly (Sanchez
et al., 2010). The issue for drug discovery then became how
to predict which classes of drugs would exhibit this phenom-
enon and which would not. As many of the targeted therapies
matured in the late 1990s, it became increasingly difficult
to manipulate the molecules to overcome resistance. Multiple
generations of small molecule inhibitors existed for each
validated target. Many unsuccessful attempts were maderights reserved
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lack of success perhaps reflects the decades of focused medic-
inal chemistry efforts aimed at targets like DHFR and thymidylate
synthase and the relatively rigid and uncompromising nature of
their active sites.
Validated Targets
Many parasitologists have focused on identifying targets through
genetics and understanding metabolism. These efforts led to the
identification of a number of protein targets that were presump-
tively essential. The sequencing of P. falciparum,which revealed
that 60% of its proteins have no orthologs in humans (Gardner
et al., 2002), accelerated this approach. However, genetic
essentiality alone does not confer validation, because drugs
must be able to abrogate function in the intracellular context
and possess balanced efficacy, bioavailability, and toxicology.
For example, cysteine proteases, such as falcipains, are critical
for many cellular processes, particularly catabolism of hemo-
globin and merozoite egress (Rosenthal, 2011), and nonspecific
cysteine protease inhibitors can kill the parasite (Joachimiak
et al., 2001). However, no falcipain inhibitor has been success-
fully transitioned to the clinic because of issues associated
with pharmacokinetics and toxicology (Ettari et al., 2010). Similar
scenarios have played out with other proposed targets such as
enoyl-ACP reductase (FabI), although in that case it did lead to
a proposition that the treatment outcome would be improved
if the target were addressed in liver rather than blood stages
(Yu et al., 2008). For these reasons, the number of validated
drug targets remains rather limited.
Validated Chemotypes
The third major constraint is the relatively small number of
antimalarial chemotypes as starting points for drug discovery
programs. In a recent review, we estimated that there are
fewer than 30 small molecule scaffolds with bona fide in vivo
activity against P. falciparum (Smithson et al., 2010). Even
among the examples that are active in vivo, only a small number
prove themselves in clinical development—with the number of
distinct antimalarial chemotypes in the clinic being fewer than
10 (Table 1). As discussed above, essentially all of these have
been the subject of extensive medicinal chemistry campaigns
spanning decades and are unlikely to yield the types of drugs
needed to support the malaria eradication campaign. Thus,
emphasis needs to be placed on identifying new scaffolds and
developing them into viable clinical candidates.
Screening Strategies
Screening strategies to identify leads fall into three categories:
virtual screening, target-based screening, and phenotypic
screening. Many screening campaigns have been executed for
malaria in the past decade in both the academic and industrial
sectors, and here we will summarize and discuss the results of
some of these efforts.
Virtual Screening
Virtual screening for malaria is hindered by the paucity of well-
validated targets, many of which also lack structural information,
although structural genomics efforts exist (Almo et al., 2007; Fan
et al., 2008; Vedadi et al., 2007). The limited number of virtual
screening studies that have produced viable preclinical candi-
dates for malaria makes it difficult to assess the power of the
approach (Nicola et al., 2007; Penna-Coutinho et al., 2011). As
new validated targets emerge, it is likely that this approach,Chemistry & Biolotogether with classical structure-based drug design, will play a
more important role.
Target-Based Screening
Target-based screening has dominated drug discovery efforts in
the past few decades. As an example, at GSK, lactate dehydro-
genase (LDH), FabI, dihydroorotate dehydrogenase (DHODH),
and thioredoxin reductase (TrxR) have been screened against
the full standard corporate screening library, and, in some cases,
also against focused sets of compounds enriched with known
inhibitors of orthologous enzymes.
Inhibition of LDH was pursued by many groups (Cameron
et al., 2004; Choi et al., 2007a, 2007b; Granchi et al., 2010). A
GSK high-throughput screening (HTS) campaign tested
500,000 compounds and identified azole derivatives as selective
inhibitors of Plasmodium LDH relative to human LDH (Cameron
et al., 2004). Although extensive lead optimization produced
derivatives with whole cell activity and partial efficacy in malaria
animal models, efficacy levels warranting further development
could not be achieved, and anti-parasitic activity could not be
linked to enzyme inhibition. These results led to the conclusion
that LDH is not druggable. TrxR met a similar fate (Buchholz
et al., 2010).
FabI is a validated druggable target for antibacterials (Heerd-
ing et al., 2001), and the Plasmodium ortholog seemed likely to
be a good antimalarial target (Perozzo et al., 2002; Surolia and
Surolia, 2001). Three GSK HTS campaigns looking for enzymatic
inhibitors of FabI using more than 900,000 compounds identified
three chemical families of tractable hits. Optimization of the
three chemotypes, directed by co-crystal structures, resulted
in highly potent inhibitors of the enzyme with clear structure-
activity relationships (SARs). However, whole-cell activity did
not correlate with enzymatic potency. Efforts to confirm the
target validation finally led to the realization that FabI is dispens-
able during the intraerythrocytic cycle (Vaughan et al., 2009; Yeh
and DeRisi, 2011; Yu et al., 2008). This project was subsequently
abandoned.
DHODH was originally chosen because it was hypothesized
that the main role of the electron transport chain might be to
provide an electron sink for DHODH (Gutteridge et al., 1979).
This hypothesis was pharmacologically confirmed later (Baldwin
et al., 2005). An enzymatic HTS at GSK using 2,000,000
compounds identified five novel families of inhibitors. They are
being held as possible backups for the triazolopyrimidine series
currently in preclinical development (Coteron et al., 2011).
Phenotypic Screening
Experience in antibacterial and antifungal drug discovery
showed that it is more difficult to add cell permeability without
cytotoxicity to an enzymatic inhibitor through medicinal chem-
istry efforts than to find the target of a selective hit from a growth
inhibition screen. A recent study showed that phenotype-based
screens identified more first-in-class small molecules between
1999 and 2008 than other screening methods (Swinney and
Anthony, 2011). Therefore, phenotypic screening seems a logical
approach of choice for lead identification efforts. Additionally,
inhibitors identified in phenotypic screening are guaranteed to
act against their antimalarial target in its intracellular context,
with physiologic concentrations of substrates and effectors.
Determining the mode of action for novel hits remains a chal-
lenge, but new technologies, including genetics (Diaz et al.,gy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 117
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The historical chemotypes and their targets.
118 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved
Chemistry & Biology
Review
Chemistry & Biology
Review2006; Rottmann et al., 2010), cheminformatics (Plouffe et al.,
2008), and proteomics (Guiguemde et al., 2010) are proving
successful.
Publicly Disclosed Screening Results
Three groups, from academia (St. Jude Children’s Research
Hospital) (Guiguemde et al., 2010), industry (GSK) (Gamo et al.,
2010), and academic/industry consortia (Novartis) (Plouffe
et al., 2008) have reported the results of phenotypic HTS
campaigns, and the structures of thousands of active com-
pounds have been deposited in public databases (https://
www.ebi.ac.uk/chemblntd/). A number of other screens are still
ongoing, but this work remains unpublished.
The St. Jude Children’s Research Hospital group screened
300,000 compounds against intraerythrocytic P. falciparum
(3D7 strain) at a concentration of 7 mM (Guiguemde et al.,
2010). The most efficacious 1,300 of these compounds were
subjected to concentration-response experiments against
multiple strains of P. falciparum as well as counter-screening
against multiple mammalian cell lines, leading to 560 validated
hits with potency at concentrations less than 2 mM against all
strains of malaria tested and at least 10-fold selectivity against
mammalian cells. A structurally diverse set of 170 compounds
was selected from these hits and subjected to extensive profiling
designed to illuminate mechanisms of action. Of the validated
hits that were fully profiled, 80% appeared to have novel mech-
anisms of action and no cross-resistance to existing drugs.
At GSK, 2,000,000 compounds were screened against intraer-
ythrocytic P. falciparum (Gamo et al., 2010). More than 19,000
primary hits inhibited growth by more than 80% at 2 mM. Retest-
ing and counter-screening for LDH inhibitors left 13,500
confirmed hits, referred to as the Tres Cantos Antimalarial Set
(TCAMS).When tested at 10 mM, only 1,982 compounds blocked
HepG2 growth by more than 50%, leaving roughly 11,500 vali-
dated hits. Most of the compounds were also active against
multi-drug resistant strains of P. falciparum.
At Novartis, a proof-of-concept screen was performed with
the Novartis natural products library of about 12,000 pure
compounds, yielding 275 hits. After reconfirmation and assess-
ment of cytotoxicity, 17 compounds were selected for further
characterization based on their favorable selectivity index (high
potency and low cytotoxicity) (Rottmann et al., 2010). After this
initial pilot screen, a larger screen of a non-proprietary collection
(about 800,000 compounds) was carried out and identified 7,500
primary hits. Dose response studies gave 5,655 hits with 50%
inhibitory concentration (IC50) values less than 1.25 mM and
selectivity of at least 5-fold against two mammalian cell lines.
About 200 distinct chemical classes were further prioritized for
hit triage and early hit-to-lead chemistry activity.
Chemistry
Composition and Diversity of the Screening Sets
Generally, the screening compounds were selected to provide
diversity and were filtered to remove compounds with predicted
poor absorption, distribution, metabolism, and excretion (ADME)
properties. The Novartis natural product collection, while di-
verse, was not prefiltered for ADME properties. The calculated
properties were consistent across all three libraries with average
molecular weights of 375 Da and an average calculated partitionChemistry & Biolocoefficient (ClogP, measuring lipophilicy) of 3.4. The physio-
chemical characteristics and scaffold composition of the collec-
tive hits were analyzed to determine the constraints placed on
their activity by the use of whole cell screening.
The distribution of seven relevant physiochemical properties
(such as molecular weight, hydrophobicity, and counts of atoms
or hydrogen bond donors/acceptors) was statistically analyzed
for FDA-approved small molecule drugs, the hits, and screening
compounds (commercial HTS, natural products, fragments)
using linear discriminant analysis to determine how the property
distributions of the hits differed from or were similar to those of
the originating compound collections (Figure 1) (Nichols, 2011).
Generally, this analysis followed our prior work with screening
libraries and can be related to cellular and systemic bioavail-
ability (Shelat and Guy, 2007). The first two ordinates included
large contributions from Oprea complexity (Allu and Oprea,
2005), molecular weight, logP, and hydrogen bond acceptors.
The antimalarial hit sets did not fully encompass the distributions
of properties of most of the approved drugs (shaded area) but
were significantly shifted toward higher molecular weight and
increased hydrophobicity as well as lower number of hydrogen
bond donors, decreased solubility, and smaller polar surface
area. The same trend was observed in comparison with the
originating HTS libraries. This shift was unexpected for a cellular
screen, which more typically yields hits with properties that
overlay those of most approved drugs. This finding, from
independent compound collections selected to be ‘‘drug-like/
lead-like’’, strongly suggests that the parasite has unique
requirements for activity, probably associated with the need to
cross two different cell membranes to reach the targets and
the unusual environment in the erythrocyte.
The analysis of scaffolds (Figure 2) followed our previously re-
portedmethods (Shelat and Guy, 2007). Each cluster in the figure
represents a set of closely related scaffolds (‘‘scaffold family’’);
the size and shape of the nodes represent the number of mole-
cules derived from the scaffold and the presence of one or more
highly potent hits (EC50 < 100 nM), respectively. The three largest
scaffold families in the aggregate hit set arequinolone, indole, and
benzoimidazole. There was a high degree of similarity at the scaf-
fold level between the three hit sets. The lowest overlap was
between GSK and Novartis, which shared only 50% of the scaf-
folds (Tanimoto similarity > 0.8, EPFP_4 fingerprint). St. Jude
shared 63% with GSK and 76% with Novartis. Overall, there
was a low level of similarity with scaffolds from existing drugs
(roughly 25%),whichcould indicate that thecritical targets inPlas-
modium and humans are significantly different in terms of the
molecules that they ‘‘like.’’ Another key finding is that while each
library contained most active scaffold families, the most active
compounds in a scaffold family tended not to be shared between
libraries. For example, the inset in Figure 2 shows a scaffold family
in greater detail. All three groups sampled from the 1,2,3,4-tetra-
hydroisoquinolone scaffold and identified potent 1-phenyl substi-
tuted analogs (pink diamonds). However the GSK and Novartis
groups identified potent, closely related analogs (red and ma-
genta diamonds), yielding a substantially different picture of the
structure activity-relationships in this series. In fact, all three
groups possessed unique analogs that could have informed hit
evolution. Only integration of the data from multiple screens al-
lowed identification of all of the well-validated active compounds.gy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 119
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Figure 1. Physiochemical Characteristics of Validated Antimalarial Hits
Linear discriminant analysis of the physiochemical characteristics of validated HTS hits compared with FDA-approved small molecule drugs (oral and parenteral),
commercially available HTS compounds, known natural products, and commercially available fragments. Shading represents the density of the distribution of
approved drugs within the space. Lines represent the perimeter of the space containing 90% of the described compound collections. The composition of each
LDA ordinate is described by the list of the physiochemical properties, sorted in order of decreasing magnitude and colored according to sign (red = negative
contribution; blue = positive contribution). Approved antimalarial drugs are depicted by open circles, with structures. The potent subset of each hit set is
rescricted to compounds with EC50 < 100 nM. Despite all three libraries being designed to overlay the centroid of the drug space, each screen selected
compounds that were significantly shifted away from this centroid.
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identification of antimalarial chemotypes and the need to pool
as much good quality screening data as possible.
High-Priority Leads
Each group pursued the development of a select series of novel
leads identified in the screening efforts. The disclosure of the
results from these studies has begun, with some now in literature
and some orally disclosed. The lead series that have been
actively pursued and publicly disclosed by each group are
summarized in Table 2.
The St. Jude group carried out a program of profiling the hit
series that involved four major phases (Guiguemde et al.,
2010). In the first phase, sets of analogs were constructed for
each series to reveal any SARs. Next, these analog sets were
tested against a wide panel of strains of P. falciparum to empir-
ically establish which series had no cross-resistance with exist-
ing antimalarial drugs. At the same time, the compounds were
tested against a panel of mammalian cell lines and parasites to120 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd Allestablish any appreciable cytotoxicity and selectivity for malaria
relative to other protozoa. Third, the series were profiled against
a large panel of validated and proposed targets for malaria,
using biochemical and biophysical methods to eliminate any
that acted by already-known mechanisms. Finally, a select set
of compounds was subjected to rapid in vivo testing to establish
bioavailability and efficacy using pharmacodynamic models.
Following what was learned in these studies, the St. Jude group
narrowed its efforts to three validated series: the diaminonaph-
thoquinones, the dihydroisoquinolones (DHIQs), and the dihy-
dropyridines. Each represented a novel chemotype with a
presumptive novel mechanism. In preliminary work, each series
had members that were orally bioavailable in mice. All were well
tolerated in mice, and each series had at least one example that
lowered parasitemia in murine P. bergheimodels. The DHIQs are
currently in late lead optimization, and the other two series are
just entering the lead optimization stage.
The GSK group carried out an extensive profiling effort to
prioritize hits from the TCAMS set (Caldero´n et al., 2011). Therights reserved
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folds distinct from known antimalarial chemotypes that were
hypothesized to be free from cross-resistance. Further analysis
focused on those that were chemically tractable, to allow rapid
identification and synthesis of derivatives to establish SARs,
and that had physicochemical properties compatible with oral
bioavailability. The first series to be prioritized from TCAMSusing
the above criteria was that of the cyclopropyl carboxamides
(Sanz et al., 2011). The original hit was both highly potent
against multi-drug-resistant strains of P. falciparum and free of
cytotoxicity against a panel of five mammalian cell lines. The
series was judged to be chemically developable, and additional
structural analogs were procured or synthesized. Testing of
these compounds validated the carboxamides as a novel anti-
malarial chemotype. In subsequent testing, individual com-
pounds showed oral efficacy in a mouse model of P. falciparum
infection with potencies similar to that of chloroquine. During the
work aimed at selecting resistant mutants for target identifica-
tion, it was noted that a high level of resistance arose at unusually
high frequencies. Consequently, further drug development activ-
ities have been halted and await elucidation of the exact molec-
ular target and the mechanism of resistance (Sanz et al., 2011).
The GSK group recently developed a different approach to
select chemical series from the TCAMS set with an increased
focus on favorable drug-like properties without previous charac-
terization of solubility or pharmacokinetic properties using an
in vivo efficacy screening with oral administration in a simplified
P. berghei mouse model. Several chemical series with potent
oral efficacy have been identified and are being characterized.
The Novartis group used a stringent triage process to select
leads with favorable physiochemical properties and strong
structure activity relationships (SAR) within the screening set,
and, often, robust reduction of parasitemia in the P. berghei
mouse model. The first series reported was a novel benzamide
scaffold that was subsequently optimized to afford a compound
with good activity against P. falciparum (Wu et al., 2009). Another
series that progressed was the 1H-imidazol-2-yl-pyrimidine-4,6-
diamines (Deng et al., 2010). The next series that was reported by
this group was the spiroindolones, including NITD609, which is
currently in phase 1 testing and is expected to enter phase 2
trials later this year (Rottmann et al., 2010; Yeung et al., 2010).
The current preclinical focus is on the imidazolpiperazine series,
including front-runner GNF156, which is anticipated to enter
phase 1 trials in early 2012 (Wu et al., 2011). These remarkable
outcomes, with two compounds in clinical trials within 5 years
of the screen, demonstrate the effectiveness of the phenotypic
screening approach.
Target Identification
Target identification and validation are generally perceived as
critical components of drug discovery. However, this has not
always been the case. Especially for antimicrobials, many drugs
currently in use were discovered using the phenotypic paradigm
(Keiser et al., 2010). A 2011 study reported that, in the preceding
decade (Swinney and Anthony, 2011), 28 first-in-class drugs
were discovered using phenotypic screens versus 17 with
target-based screens. Using phenotypic methods to identify
hits, empirical medicinal chemistry to optimize them, and in vivo
pharmacokinetic, toxicokinetic, and pharmacodynamic modelsChemistry & Bioloto understand their function, a drug discovery program can
remove target identification from the critical path needed to
move new drugs to the clinic (Figure 3). However, having a target
for a small molecule series is practical and useful because it
allows the use of both structural and biochemical methods (Stoll
et al., 2011; Wilson and Lill, 2011) and can direct the focus of
toxicologic studies (Garcia-Serna and Mestres, 2010; Garcia-
Serna and Mestres, 2011). Additionally, in malaria drug develop-
ment, knowing a target for the drug facilitates the study of the
acquisition of resistance. Finally, identifying the target opens
the possibility of identifying backup molecules hitting the same
target and thus better prioritizing efforts. Thus, while not
mission-critical, target identification remains an important part
of malaria drug discovery.
Many groups have turned to genome scanning when stable
resistant mutants can be generated (McNamara and Winzeler,
2011). There are now several examples of successful target iden-
tification efforts that relied on the induction of drug resistance
and the subsequent characterization of the mutations that
conferred the resistant phenotype (Dharia et al., 2010; Istvan
et al., 2011; Nam et al., 2011). Using this approach, the putative
Ca2+-dependent ATPase, encoded by the gene PfATP4, was
identified as a candidate target for the spiroindolones (Rottmann
et al., 2010). Using a similar approach with the imidazolopipera-
zine scaffold, drug resistance against this chemotype was found
to be mediated by mutations in a gene of unknown function that
was named PfCarl (cycloamine resistance locus, or Pf0970w)
(Meister et al., 2011). An unanswered question in the field is
how many new mechanisms of action have been encompassed
by the current cellular/phenotypic hits. Based on our experi-
ences in characterizing the hit sets, we believe that only a small
set of new mechanisms may have been identified and that this
possibility provides a strong impetus for a concerted effort
toward systematic target identification globally using these hits
(Garcia-Bustos and Gamo, 2011).
The St. Jude group used several strategies to identify potential
targets of its hits. Reverse chemical genetic techniques were
used to profile the set of antimalarial hits (172) against 66 cellular
proteins, including a panel of validated drug targets by direct
enzyme inhibition assays, and against a panel of predicted
druggable targets by binding assays (thermal melt) (Guiguemde
et al., 2010). They also looked for differential sensitivity to the
compounds in specific parasite strains, either mutants with
genetic linkage to drug resistance (V1S cell line, quadruple
DHFR mutant) or transgenic parasites harboring the putative
target (PfDHOD) (Painter et al., 2007). The combination of these
two target identification strategies allowed identification of
known targets for roughly 20% of the screening hits. The only
targets giving functional novel inhibitors were the classic ones
that have been well validated.
At GSK, rescreening the TCAMS hits against a strain of
P. falciparum overexpressing DHODH identified roughly 400
inactive compounds, indicating they probably targeted electron
transport. Proguanil, a known antifolate, has been previously
observed to fully restore the inhibitory activity of cytochrome
b1 inhibitors but not DHODH inhibitors against this strain
(Ke et al., 2011). This approach identified both cytochrome b
(14 novel chemotypes) and DHODH inhibitors (12 novel chemo-
types). Antifolates can be identified by supplementing the growthgy 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved 121
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Figure 2. Scaffolds Observed in Validated Antimalarial Hits
A network graph showing the distribution of scaffolds within the hit sets in comparison with one another. Scaffolds were defined from molecules using the
Schuffenhauer fragmentation algorithm (Schuffenhauer et al., 2007a, 2007b), but requiring at least two rings unless the molecule was acyclic or possessed only
one ring. Scaffold nodes were arranged into parent-child hierarchies based on substructure relationships. The resulting root scaffolds were clustered using
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biosynthesis pathway by adding geranylgeranyol or isopentenyl
pyrophosphate (Yeh and DeRisi, 2011), which shifts the IC50 of
inhibitors of those pathways.
At Novartis, the full set of confirmed antimalarial hits was
screened with biochemical assays against nine putative drug
targets. None of these screenings yielded a direct correlation
between potency against a target and potency in the whole
cell assay. Thus, no chemotype could be unambiguously
assigned as an inhibitor of any of the nine targets screened
(Crowther et al., 2011). The Novartis hit set was also screened
with six other targets; the kinases PfCK2 PfCDPK 1 and 5, and
PfGSK3; and the redox enzymes TrxR and glutathione reduc-
tase. That study yielded a similar outcomewith no clear evidence
that the antimalarial activity of those compounds could be attrib-
uted to the inhibition of any of the nine molecular targets.
Recently, an in vitro liver-stage assay (Silvie et al., 2003) was
used to screen the Novartis hit set to identify compounds with
both erythrocytic and hepatic antimalarial activity. The results
of that screen showed that the overlap between blood and liver
stages was fairly small, with only 229 compounds having an IC50
less than 1 mM in the liver-stage assay (Meister et al., 2011). Inter-
estingly, whereas one spiroindolone, NITD609, was found to
be completely inactive in this assay, the imidazolopiperazines
showed potent activity that translated into robust causal prophy-
lactic activity in the P. berghei malaria mouse model. Going
forward, such approaches could be used to prioritize medicinal
chemistry activities.
Conclusions and Future Directions
The recent publication of thousands of new antimalarial mole-
cules provides a path forward in the field of drug discovery.
Although these results are promising, especially with one
compound already in clinical trials, it is important to bear in
mind that for a new antimalarial, the risk of failure in phase 2 trials
is estimated at 50% (Pink et al., 2005). Therefore, there remains
a clear need to take full advantage of all of the potential afforded
by the existing antimalarial hits to understand what new mecha-
nisms of action andmediators of resistance can be identified and
to use these learnings to guide new drug development. This will
require strategic adjustments in the malaria drug discovery
community, including addressing technical gaps in knowledge
and improving global efforts by mobilizing the entire community
with improved public disclosure and sharing of data.
A major technical gap is the lack of early identification of
potential drug partners for combination therapy and the evalua-
tion of their potential for synergy or antagonismwith current anti-
malarials. The World Health Organization has mandated that
all future chemotherapy for malaria will use drug combinations
(Anonymous, 2001). Since future drugs will always be used in
combination, they should be free of antagonism with potential
partner drugs. It is labor-intensive to test large numbers ofTanimoto distance (FCFP_4 fingerprint) to generate 399 scaffold families. Each fam
and cluster membership define graph edges. Scaffold nodes are colored by libra
shaped according to whether or not at least onemolecule from the scaffold is pote
families are shown. Each group independently identified most scaffold families, a
was highly variable. As a result, often only one library contained themost potent m
scaffolds among the group.
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linked to CYP450 induction or inhibition or mismatched half-
lives, are common. A method to estimate half-lives with the
throughput to handle the tens of thousands of compounds in
the published antimalarial sets would be extremely valuable in
prioritizing compounds for further development.
Another technical gap is the lack of simple and powerful
assays to determine whether drugs are cytocidal or cytostatic
in effect as well as the rate of the effect. Fast-acting cytocidal
drugs are desired because they not only alleviate the symptoms
of malaria, but they can also delay the onset of drug resistance.
Current methods involve long treatment of cultures for fixed
periods of time, followed by removal of the drug and determina-
tion of effect at a later time. Such methods are labor-intensive,
although significant improvements have been reported. The
only widely accepted method for determining cytocidality is
the clonal dilution assay, which requires weeks of continuous
culture and is extremely labor-intensive (Rathod et al., 1997).
Recently, a medium-throughput PCR protocol for determining
cytocidality was described (Bahamontes-Rosa et al., 2011),
but it is unsuitable for handling large numbers of compounds.
In addition to determining the speed of parasite killing, assays
that couldmeasure the potency of compounds against individual
stages of the intraerythrocytic parasite life cycle would be very
useful, because a lead compound should be active against all
stages. Finally, high-throughput assays against other stages,
such as gametocytes and liver stages, are needed as well.
Such assays are currently under development in several labora-
tories (Adjalley et al., 2011; Buchholz et al., 2011; Dembele et al.,
2011).
Because drug resistance is the main obstacle to antimalarial
drug discovery, it will be critical to assess the potential for drug
resistance of lead compounds progressing toward becoming
a clinical candidate. Medium-throughput assays to determine
parasite resistance acquisition frequencies under drug pressure
(Gassis and Rathod, 1996; Rathod et al., 1997; White and Pong-
tavornpinyo, 2003) would be extremely useful.
Another challenge is understanding the mechanism of action
for newly validated hits. Currently, biochemical methods are
limited to available proteins, and generating drug-resistant para-
sites for genome scanning is time-consuming. As discussed
above, utilization of high-throughput biochemical screens to
select inhibitors for potential targets from the various hit sets
has given very low hit rates. This is probably more due to poor
validation of the interrogated novel targets rather than to the
methods themselves (Pink et al., 2005).
The identification of essential genes encoding drug targets is
still a challenge. Strobel (Strobel and Arnold, 2004) speculated
that eukaryotes have approximately 400 essential eukaryotic
genes. As has previously been pointed out in analyzing other
organisms, using the reasonable assumption that enzymes,
receptors, and channels are the most likely targets for smallily was then assigned a node. Parent-child scaffold substructure relationships
ry membership, sized by number of molecules derived from the scaffold, and
nt (EC50 < 100 nM). Structures of the root scaffolds from the ten largest scaffold
lthough the coverage of each scaffold by analogs present in individual hit sets
ember of a given scaffold. Thismay have driven the divergence in ‘‘high priority’’
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Table 2. High-Priority Series from Each Group
Molecule Series Example Institution Development Stage
O
O
O
O N
H
F
O
Dihydropyridine SJ000025081 SJCRH Lead optimization
Diaminonaphthoqinone SJ000030570 SJCRH Lead optimization
Dihydroisoquinoline SJ000101247 SJCRH Preclinical
Carboxamide GSK2611622A GSK Lead optimization
Indoline TCMDC-139046 GSK Lead optimization
Alkylpyrazole TCMDC-134142 GSK Lead optimization
124 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd All rights reserved
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Table 2. Continued
Molecule Series Example Institution Development Stage
Thienopyrazole TCMDC-123580 GSK Lead optimization
Aminopiperidine TCMDC-124833 GSK Lead optimization
NH
Cl
NH
O
H
N
F
Cl
Spiroindolone NITD609 Novartis Phase I
Imidazolo piperazine Novartis Preclinical
Benzamide Novartis Lead optimization
Pyrimidine-4,6-diamine Novartis Lead optimization
In retrospective analysis, it is clear that each group independently detectedmost of the chemotypes present in this table, but, although uncoordinated,
each group focused later efforts on a restricted set of series identified from their screens.
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Figure 3. Phenotypic Drug Discovery Strategy for Malaria
The phenotypic strategy utilizes early deployment of cellular and pharmacologic constraints on molecule selection, leading rapidly to compounds with a high
probability of activity in vivo. This pushes target identification and validation to later in the process, off the critical path. However, understanding themechanism of
action and acquisition of resistance are related.
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tractable essential targets for malaria probably is around 100
to 200 (Hopkins and Groom, 2002; Landry and Gies, 2008). In
an ideal scenario, where the available hit sets serve all possible
druggable targets, the probability of detecting inhibitors with
an assay using a genetically validated enzyme would be roughly
50%. Because most putative targets in Plasmodium lack strin-
gent experimental validation, and the limited work with the hit
sets shows that they can contain 10 or more chemical families
hitting the same target (tested for DHODH, cytochrome bc1
complex, or others), the true probability is much lower, as dis-
cussed above. On the other hand, compounds capable of inhib-
iting certain targets, such as protein kinases (Doerig and Meijer,
2007), are overrepresented (Gamo et al., 2010), so screening
such target classes is almost assured to identify biochemical
inhibitors. Nevertheless, identifiying the targets acted upon by
the current hit sets is a critical step toward enabling the next
generation of drugs.
Finally, there is a need to adjust the research culture within
malaria drug discovery to make up for the poor resourcing
compared with other diseases. For example, in the United
States, the National Institutes of Health expect to spend roughly
$5.8 billion on cancer research and $2.1 billion on cardiovascular
research, but only $134 million on malaria. We point to two key
areas: (1) more rapid public disclosure and sharing of relevant
data coming from malaria drug discovery efforts to enable
communitywide learning and crowdsourcing (FitzGerald, 2011;
Robertson andMayr, 2011); and (2) a freely accessible collection
of physical samples of well validated antimalarial hits and
leads with annotated functional data to enable the study of basic
malaria biology. Both of these efforts are under way, and
although there is a general shift, there needs to be stronger
adoption by the community (Bhardwaj et al., 2011; Lessl et al.,
2011). Private-public partnerships have laid the groundwork for
the discovery of new antimalarial chemical space and will
continue to do so (Burrows et al., 2011; Nwaka and Ridley,
2003). In addition, data management interfaces are becoming
available in themalaria drug discovery field to allow investigators126 Chemistry & Biology 19, January 27, 2012 ª2012 Elsevier Ltd Allto query and exchange information. Such examples are Hit
Explorer Operating System, Collaborative Drug Discovery,
ChEMBL (Gaulton et al., 2012), and PubChem. Public disclosure
can stimulate scientific collaborations and, more importantly,
can decrease the attrition of drug failures. The failure rate was
estimated at 70% at the exploratory early discovery stage based
on data from Medicines for Malaria Venture (MMV) (Nwaka and
Ridley, 2003).
We believe that the next step to further drive malaria drug
discovery will be the establishment of a well-validated collection
of novel antimalarial compounds to be used community-wide for
the study of mechanisms of action and identification of targets.
One of the authors (T.T.D.) coined the term ‘‘malaria box’’ to
describe such a collection of compounds. A preliminary malaria
box has already been established by MMV, and distribution is
beginning. We propose a global consolidation and expansion
of the malaria box—to provide higher quality lead materials,
stronger chemical diversity, and an open source data exchange
component (Figure 4). The malaria box should be a physical
depository of high-quality chemical materials of known concen-
tration, purity, and identity. They should not be just ‘‘hits,’’ but
rather compounds that have been extensively characterized.
For example, the collection optimally should be restricted to vali-
dated series with known SARs, containing a few analogs each,
as well as inactive but structurally related control compounds.
An ideal collection would include mostly compounds that are
active in vivo. The malaria box should be actively managed to
keep its size workable for most biology groups, meaning that it
will contain no more than a few hundred diverse compounds.
Thesamedistributioncenter for themalariaboxshouldmaintain
full annotation of the compounds, includingbiological data, ideally
confirmed by independent laboratories or orthogonal methods.
Utilization of the malaria box by investigators should carry a
requirement to make data available to the community through
this mechanism. Ideally, each compound would have an associ-
ated synthetic route to enable crowd-driven SAR studies.
The malaria box should be available to investigators upon
request and as freely accessible as reasonable. The responsiblerights reserved
Figure 4. The Malaria Box Concept
The malaria box is a single clearinghouse that would warehouse data, models,
and physical compounds and serve as a hub for collaboration. Community
members would release constituents to the box, which would then be an open
source to facilitate further work on parasitology, chemistry, pharmacology,
and model building. To access the contents of the box, collaborators would
need to agree to participate in the open source model.icipate in the open
source - crowdsourceing contents of the box collaborators woudl k on para-
sitology, chem
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ments on the work to be done, but rather would distribute
reasonable quantities for cellular work. Intellectual property
should be deliberately nullified, and there should be a require-
ment that studies be published if at all possible. While funding
such an endeavor may seem daunting, a similar depository
exists for malaria cell lines and reagents: the Malaria Research
and Reference Reagent Resource Center. GSK has taken a
similar approach to enabling kinase biology with its Published
Kinase Inhibitor Set. These examples indicate it should be
possible to convince all relevant stakeholders to participate
and to identify sources to cover costs.
The malaria box will operate at two levels: first, as an open
source providing data and chemicals and, second, as the plat-
form where the scientific community would engage in discus-
sions, contribute new data, and self-correct in a way similar to
Wikipedia. Ultimately, each scientist around the world would
be able to participate in guiding the drug discovery process.
We anticipate, in the context of malaria, a disease with low
economic reward for the pharmaceutical industry; such
a concept will not only accelerate the discovery process but
also will increase the success rate.
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